IFNA17 and benign prostatic hyperplasia: Results showed that the IFNA17 cytokine was upregulated in primary prostate cancer samples compared to the benign prostatic hyperplasia (BPH) group, and higher levels of IFNA17 were found in CRPC patients than in the BPH or primary prostate cancer groups (Fig. 4M).